Research programme: intranasal interferon beta - Aegis/Johns Hopkins/Nerveda

Drug Profile

Research programme: intranasal interferon beta - Aegis/Johns Hopkins/Nerveda

Alternative Names: Non-injectable interferon beta - Aegis/Johns Hopkins/Nerveda

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aegis Therapeutics; Nerveda
  • Developer Aegis Therapeutics; Johns Hopkins University; Nerveda
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 01 Aug 2016 No development reported - Preclinical for Multiple sclerosis in USA (Intranasal)
  • 12 Jan 2009 Preclinical trials in Multiple sclerosis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top